A Phase 1/2 interventional study of Vepdegestrant and Vepdegestrant in Breast Cancer, sponsored by Arvinas Estrogen Receptor, Inc.. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Arvinas Estrogen Receptor, Inc. · Phase 1/2, Interventional, and Treatment
Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) · Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) · Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) · Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) · Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing vepdegestrant in Breast Neoplasms — 1 open to participants now, 6 under way, 2 of them phase 3. vepdegestrant · Breast Neoplasms.
Among the 12 studies testing vepdegestrant in Breast Neoplasms, this one is the 3rd largest by enrollment, is the only one that started in 2019, is one of 5 in phase 1/2, and was the 2nd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →1 of the 12 studies testing vepdegestrant in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:
QuantumLeap Healthcare Collaborative · Sites in United States
Ages 18+
By country, each count listing its studies:
vepdegestrant: first FDA approval 2026 (VEPPANU). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, vepdegestrant is the treatment under test here. Read study by study →
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 2
First in 2010; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 219 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 48 across the 12 interventional studies. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 12 have an industry lead sponsor. The 4 most frequent:
Arvinas Estrogen Receptor, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Arvinas Estrogen Receptor, Inc. has 2 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing vepdegestrant in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909397Phase 3PfizerVepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer | 2026-12-30 |
| NCT05548127PfizerTACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | 2027-03-24 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies testing vepdegestrant in Breast Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was a Phase 1/2 dose escalation and cohort expansion study and assessed the safety, tolerability and anti-tumor activity of ARV-471 alone and in combination with palbociclib (IBRANCE®) in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) locally advanced or mBC, who had received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting.
The criteria were revised on the registry on Sep 29, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A, Part B, and Part C:
Part A:
- Participants must have received at least 2 prior endocrine regimens in any setting (, adjuvant or advanced/) a CDK4/6 inhibitor and up to 3 prior regimens of cytotoxic chemotherapy in the locally advanced or metastatic setting.
Part B:
Part C:
Exclusion Criteria:
Part A, Part B, and Part C:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received vepdegestrant 30 milligrams (mg) orally once daily (QD) with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after the end of treatment (EOT) or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant
Participants received vepdegestrant 60 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant
Participants received vepdegestrant 100 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant
Participants received vepdegestrant 120 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant
Participants received vepdegestrant 180 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant
Participants received vepdegestrant 200 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant
Participants received vepdegestrant 360 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant
Participants received vepdegestrant 500 mg QD or 250 mg twice daily (BID), orally with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant
Participants received vepdegestrant 700 mg QD or as BID dose (400 mg in the morning and 300 mg in the evening), orally with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant
Participants received vepdegestrant 200 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant
Participants received vepdegestrant 500 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant
Participants initially received vepdegestrant 180 mg tablets orally QD with food then upon availability of the 100-mg tablets was rounded up to 200 mg QD, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed up for survival after at least 3 months after the EOT or Follow-up visit (whichever occurred later).
Drug: Vepdegestrant · Drug: Palbociclib
Participants received vepdegestrant 200 mg orally QD with food, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant · Drug: Palbociclib
Participants received vepdegestrant 400 mg orally QD with food, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant · Drug: Palbociclib
Participants received vepdegestrant 500 mg orally QD with food, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant · Drug: Palbociclib
Participants initially received palbociclib 100 mg orally QD starting on C1D1, for 21 days followed by 7 days off and then received vepdegestrant 200 mg QD with food on C1D9, given continuously (28-day cycle). Palbociclib was administered alone from C1D1 to C1D8 prior to starting vepdegestrant on C1D9. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Drug: Vepdegestrant · Drug: Palbociclib
Vepdegestrant administered QD for 28-day cycles
Also known as: ARV-471
Vepdegestrant administered QD or BID for 28-day cycles.
Also known as: ARV-471
Daily oral dosages of vepdegestrant for 28 days in combination with palbociclib for 21 days
Also known as: IBRANCE®
Part A: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment
DLT was defined as any adverse event (AE) or abnormal laboratory value which were related to vepdegestrant and assessed as unrelated to mBC, intercurrent illness, or concomitant medications occurring during the first 28 days of treatment that met at least 1 of the study specified criteria.
Time frame: Baseline (Day 1) up to C1D28
Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-Related TEAEs
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. Serious AE (SAE) was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 4 years and 6 months)
Part B: Clinical Benefit Rate (CBR)
CBR: percentage of participants with summation of complete response (CR), partial response (PR) or stable disease (SD) of 24 weeks duration or longer. CR: disappearance of all target lesions (TLs) and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the longest diameter (LD) of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs.
Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)
Part C: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment
DLT was defined as any AE or abnormal laboratory value which were related to vepdegestrant and assessed as unrelated to mBC, intercurrent illness, or concomitant medications occurring during the first 28 days of treatment that met at least 1 of the study specified criteria.
Time frame: Baseline (Day 1) up to C1D28
Part C: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEs
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. SAE was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 3 years and 9 months)
Part C: Maximum Tolerated Dose (MTD)
MTD is the highest dose of a drug that can be given to participants without causing unacceptable DLTs, as determined during a clinical study.
Time frame: Baseline (Day 1) up to C1D28
Part A: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of Vepdegestrant and Its Epimer ARV-473
AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1.
Part A: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant and Its Epimer ARV-473
AUClast was defined as area under the concentration-time curve from time 0 through the last quantifiable concentration (AUClast). Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Part A: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant and Its Epimer ARV-473
Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Part A: Minimum Observed Plasma Concentration (Cmin) of Vepdegestrant and Its Epimer ARV- 473
Cmin was defined as the minimum observed plasma concentration. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15
Part A: Apparent Oral Plasma Clearance (CL/F) of Vepdegestrant
CL/F was defined as the apparent oral plasma clearance of vepdegestrant. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15
Part A: Time of Maximum Observed Plasma Concentration (Tmax) of Vepdegestrant and Its Epimer ARV- 473
Tmax was defined as the time of maximum observed plasma concentration. Based on predefined reporting convention in the SAP, summary statistics describing variability (median) was not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Part A: Accumulation Ratio for AUC0-tau (Rac [AUCtau]) of Vepdegestrant and Its Epimer ARV- 473
Rac was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Part A: Accumulation Ratio for Cmax (Rac [Cmax]) of Vepdegestrant and Its Epimer ARV- 473
Rac was calculated as the ratio of Day 15/Day 1 based on Cmax. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Part A: Effective Half-life Based on Accumulation Ratio of RAUC(0-tau) of Vepdegestrant and Its Epimer ARV-473
Effective half-life based on accumulation ratio of RAUC(0-tau). Accumulation ratio was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Part A: Epimer (ARV-473) to Parent (Vepdegestrant) Ratio for Cmax (MRCmax).
The epimer ARV-473 to parent ratio based on Cmax was reported. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Part A: Epimer (ARV-473) to Parent (Vepdegestrant) Ratio for AUCtau (MRAUCtau)
The epimer ARV-473 to parent ratio based on AUCtau was reported. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Part A: Overall Response Rate (ORR) by Investigator Per RECIST v1.1
ORR was defined as the percentage of participants with best overall response (BOR) of CR and PR as per Response Evaluation Criteria in Solid Tumours (RECIST version \[v\] 1.1). BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR.
Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 4 years and 6 months)
Part A: Clinical Benefit Rate (CBR)
CBR: percentage of participants with summation of CR, PR or SD of 24 weeks duration or longer. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs.
Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 4 years and 6 months)
Part A: Disease Control Rate (DCR)
DCR: percentage of participants with CR, PR or SD. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. DCR was based on confirmed responses. Confirmed responses were at least 4 weeks after the criteria for response were first met.
Time frame: From start of study treatment up to progressive disease or death (up to approximately 4 years and 6 months)
Part A: Progression-Free Survival (PFS) Per RECIST v1.1
PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Kaplan-Meier (KM) estimate was used for analysis.
Time frame: From start of study treatment up to progressive disease or death (up to approximately 4 years and 6 months)
Part A: Duration of Response
DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.
Time frame: From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 4 years and 6 months)
Part B: Overall Response Rate (ORR) by Investigator Per RECIST v1.1
ORR was defined as the percentage of participants with BOR of CR and PR as per RECIST version \[v\] 1.1. BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR.
Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)
Part B: Progression-Free Survival (PFS) Per RECIST v1.1
PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.
Time frame: From start of study treatment up to progressive disease or death (up to approximately 2 years and 11 months)
Part B: Duration of Response
DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.
Time frame: From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 2 years and 11 months)
Part B: Overall Survival
OS was defined as the time from first dose of the study drug until the documented date of death from any cause. KM estimate was used for analysis.
Time frame: From start of study treatment up to death (up to approximately 2 years and 11 months)
Part B: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEs
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. SAE was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs.
Time frame: From start of study treatment up to 30 days after end of study treatment (up to approximately 2 years and 11 months)
Part B: Pre-dose Concentrations of Vepdegestrant and Its Epimer ARV-473
Pre-dose Plasma concentrations of vepdegestrant and ARV-473 was reported. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Predose on C1D15 and C1D28 to C26D28
Part C: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
AUCtau was calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant \& ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant \& ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for drug-drug interaction (DDI) evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
Part C: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
Part C: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
Part C: Minimum Observed Plasma Concentration (Cmin) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
Cmin was defined as the minimum observed plasma concentration. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15 for arms with palbociclib 125 mg. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for arm with palbociclib 100 mg.
Part C: Apparent Oral Plasma Clearance (CL/F) of Vepdegestrant and Palbociclib
As planned for Part C, PK data of vepdegestrant and palbociclib for arms administered with 125 mg palbociclib was reported for C1D15. PK data of vepdegestrant data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D15 for arms with palbociclib 125 mg. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for arm with palbociclib 100 mg.
Part C: Time of Maximum Observed Plasma Concentration (Tmax) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
Tmax was defined as the time of maximum observed plasma concentration. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D8, C1D21/C2D15 for palbociclib 100 mg arms.
Part C: Accumulation Ratio for AUC0-tau (Rac [AUCtau]) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
Rac was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. As prespecified, participants in the Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg Arm were not assessed. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms.
Part C: Accumulation Ratio for Cmax (Rac [Cmax]) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
Rac was calculated as the ratio of Day 15/Day 1 based on Cmax. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. As prespecified, participants in the Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg Arm were not assessed. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms.
Part C: Effective Half-life Based on Accumulation Ratio of RAUC(0-tau) (Effective T1/2) of Vepdegestrant, Its Epimer ARV-473 and Palbociclib
Effective half-life based on accumulation ratio of RAUC(0-tau). Accumulation ratio was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12, 24 hours post dose on C1D15 for arms with palbociclib 125 mg (each cycle is of 28 days)
Part C: Epimer (ARV-473) to Parent (Vepdegestrant) Compound Molar Ratio for Cmax (MRCmax)
Epimer ARV-473 to parent ratio based on Cmax was reported. Cmax was defined as the maximum observed plasma concentration obtained from the observed concentration versus time data. As planned for Part C, PK data of vepdegestrant, ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1/C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21/C2D15. As per protocol, in 100 mg palbociclib administered arm, intensive PK sample collection not done on C1D21 was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D21/C2D15 for palbociclib 100 mg arms.
Part C: Epimer (ARV-473) to Parent (Vepdegestrant) Compound Molar Ratio for AUCtau (MRAUCtau)
Epimer ARV-473 to parent ratio based on AUCtau was reported. AUCtau was calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
Time frame: Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1 for palbociclib 125 mg arms. Pre-dose, 1, 2, 4, 6, 8 hours post dose on C1D21/C2D15 for palbociclib 100 mg arms.
Part C: Overall Response Rate (ORR) by Investigator Per RECIST v1.1
ORR was defined as the percentage of participants with BOR of CR and PR as per RECIST version \[v\] 1.1. BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR.
Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 3 years and 9 months)
Part C: Clinical Benefit Rate (CBR)
CBR: percentage of participants with summation of CR, PR or SD of 24 weeks duration or longer. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs.
Time frame: From start of study treatment until disease progression or death due to any cause (up to approximately 3 years and 9 months)
Part C: Progression-Free Survival (PFS) Per RECIST v1.1
PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.
Time frame: From start of study treatment up to progressive disease or death (up to approximately 3 years and 9 months)
Part C: Overall Survival
OS was defined as the time from first dose of the study drug until the documented date of death from any cause. KM estimate was used for analysis.
Time frame: From start of study treatment up to death (up to approximately 3 years and 9 months)
Part C: Duration of Response
DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.
Time frame: From the date of first documented confirmed CR/PR to the date of PD or death due to any cause (up to approximately 3 years and 9 months)
Participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+, HER2-) locally Advanced or Metastatic Breast Cancer (mBC) who had received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting were enrolled at sites in the United States (US).
| Milestone | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) | Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 15 | 7 | 7 | 8 | 15 | 22 | 4 | 0 | 0 | 2 | 0 | 3 | 0 | 0 |
| Treated | 3 | 3 | 14 | 7 | 7 | 8 | 15 | 22 | 4 | 0 | 0 | 2 | 0 | 3 | 0 | 0 |
| Received 180 mg in part c | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Received 200 mg in part c | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 3 | 15 | 7 | 7 | 8 | 15 | 22 | 4 | 0 | 0 | 2 | 0 | 3 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 4 | 5 | 5 | 4 | 7 | 15 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Miscellaneous | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Ongoing at data cut-off | 0 | 1 | 10 | 1 | 1 | 4 | 7 | 3 | 2 | 0 | 0 | 2 | 0 | 2 | 0 | 0 |
| Milestone | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) | Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35 | 36 | 0 | 21 | 0 | 21 | 17 |
| Treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35 | 36 | 0 | 21 | 0 | 20 | 17 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35 | 36 | 0 | 21 | 0 | 21 | 17 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 14 | 0 | 5 | 0 | 11 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 1 | 0 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Disease progression | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 |
| Withdrew: Miscellaneous | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Not treated | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Ongoing at data cut-off | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 18 | 19 | 0 | 14 | 0 | 6 | 4 |
DLT was defined as any adverse event (AE) or abnormal laboratory value which were related to vepdegestrant and assessed as unrelated to mBC, intercurrent illness, or concomitant medications occurring during the first 28 days of treatment that met at least 1 of the study specified criteria.
| Participants | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|
| Part A: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. Serious AE (SAE) was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|
| TEAEs | 3 | 3 | 14 | 7 | 7 | 8 | 15 | 21 | 3 |
| Serious TEAEs | 1 | 1 | 3 | 0 | 0 | 1 | 2 | 2 | 1 |
| Treatment-Related TEAEs | 0 | 3 | 14 | 6 | 4 | 6 | 13 | 15 | 2 |
CBR: percentage of participants with summation of complete response (CR), partial response (PR) or stable disease (SD) of 24 weeks duration or longer. CR: disappearance of all target lesions (TLs) and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the longest diameter (LD) of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs.
| percentage of participants | Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) |
|---|---|---|
| Part B: Clinical Benefit Rate (CBR) | 37.1 (21.5 to 55.1) | 38.9 (23.1 to 56.5) |
DLT was defined as any AE or abnormal laboratory value which were related to vepdegestrant and assessed as unrelated to mBC, intercurrent illness, or concomitant medications occurring during the first 28 days of treatment that met at least 1 of the study specified criteria.
| Participants | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg (Initially 180 mg)+Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) |
|---|---|---|---|
| Part C: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment | 0 | 0 | 0 |
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. SAE was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| TEAEs | 2 | 21 | 3 | 20 | 17 |
| Serious TEAEs | 1 | 8 | 1 | 4 | 6 |
| Vepdegestrant-Related TEAEs | 2 | 16 | 3 | 17 | 14 |
| Palbociclib-Related TEAEs | 2 | 21 | 3 | 20 | 17 |
MTD is the highest dose of a drug that can be given to participants without causing unacceptable DLTs, as determined during a clinical study.
| milligram | Part C - Dose Escalation Participants |
|---|---|
| Part C: Maximum Tolerated Dose (MTD) | NA |
AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| hour*nanogram per millilter (h*ng/mL) | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 250 mg | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 400 mg/300mg | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vepdegestrant: C1D1 | 1713.4 ± 6.5255 | 2963.7 ± 33.364 | 3767 ± 47.941 | 6326.2 ± 21.225 | 9580.3 ± 12.457 | 9111.2 ± 47.687 | — | 12172 ± 32.121 | — | 16784 ± 28.24 | NA ± NA |
| Vepdegestrant: C1D15 | 4051.4 ± 25.594 | 7323.7 ± 15.276 | 8009.8 ± 40.063 | 13714 ± 12.903 | 19225 ± 31.77 | 15810 ± 37.836 | 22062 ± 28.844 | 25931 ± 26.561 | NA ± NA | 34585 ± 35.453 | NA ± NA |
| ARV-473: C1D1 | 193.5 ± 4.0425 | 323.47 ± 36.121 | 425.2 ± 53.143 | 673.95 ± 19.937 | 1022.6 ± 9.9255 | 959.2 ± 43.348 | — | 1352.4 ± 37.377 | — | 1795.2 ± 26.921 | NA ± NA |
| ARV-473: C1D15 | 1279.2 ± 33.1 | 2243.2 ± 8.1246 | 2601.4 ± 42.081 | 3973.7 ± 24.443 | 5799.4 ± 34.407 | 5084.6 ± 38.893 | 8086.7 ± 47.183 | 8076.6 ± 33.749 | NA ± NA | 10198 ± 40.688 | NA ± NA |
AUClast was defined as area under the concentration-time curve from time 0 through the last quantifiable concentration (AUClast). Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| h*ng/mL | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 250 mg | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 400 mg/300 mg | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vepdegestrant: C1D1 | 599.09 ± 19.386 | 957.86 ± 17.068 | 1130.4 ± 108.47 | 2060.2 ± 25.625 | 2782.3 ± 29.217 | 2571.9 ± 43.222 | 2924.4 ± 32.312 | 3905.4 ± 38.53 | 3798.6 ± 101.63 | 5820.2 ± 31.656 | NA ± NA |
| Vepdegestrant: C1D15 | 1527.2 ± 27.151 | 2607.6 ± 8.3221 | 2979.6 ± 45.329 | 4831.1 ± 11.036 | 7083.4 ± 29.436 | 5736.7 ± 37.033 | 14833 ± 25.669 | 9382 ± 27.929 | NA ± NA | 12296 ± 32.053 | NA ± NA |
| ARV-473: C1D1 | 39.267 ± 23.637 | 56.59 ± 20.68 | 69.024 ± 165.07 | 122.5 ± 28.646 | 163.56 ± 38.77 | 157.7 ± 43.521 | 178.88 ± 47.75 | 253.86 ± 38.75 | 219.79 ± 95.555 | 361.45 ± 30.093 | NA ± NA |
| ARV-473: C1D15 | 425.26 ± 35.876 | 770.48 ± 6.2883 | 871.9 ± 48.311 | 1311.2 ± 23.677 | 1940.2 ± 34.569 | 1618.9 ± 36.407 | 5384.5 ± 47.705 | 2643 ± 32.639 | NA ± NA | 3335.2 ± 40.576 | NA ± NA |
Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| ng/mL | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 250 mg | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 400 mg/300 mg | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vepdegestrant: C1D1 | 108.88 ± 5.6696 | 194.44 ± 33.011 | 251.04 ± 40.887 | 403.68 ± 21.071 | 591.69 ± 14.076 | 533.64 ± 52.319 | 663.05 ± 18.043 | 748.38 ± 34.275 | 716.2 ± 130.53 | 1046.1 ± 31.065 | NA ± NA |
| Vepdegestrant: C1D15 | 219.21 ± 26.659 | 404.53 ± 7.6864 | 478.28 ± 41.379 | 798.83 ± 5.7971 | 1062.3 ± 27.301 | 882.6 ± 43.116 | 2212.5 ± 28.604 | 1501.6 ± 26.697 | NA ± NA | 1883 ± 30.568 | NA ± NA |
| ARV-473: C1D1 | 11.032 ± 15.269 | 19.748 ± 43.608 | 24.888 ± 41.355 | 39.324 ± 28.389 | 62.344 ± 12.975 | 58.607 ± 50.927 | 51.931 ± 25.609 | 76.925 ± 44.573 | 47.44 ± 119.4 | 98.066 ± 28.697 | NA ± NA |
| ARV-473: C1D15 | 57.645 ± 31.847 | 108.2 ± 6.0056 | 131.26 ± 44.089 | 191.08 ± 18.518 | 273.35 ± 31.598 | 233.57 ± 36.903 | 761.99 ± 50.623 | 381.65 ± 31.454 | NA ± NA | 480.42 ± 41.513 | NA ± NA |
Cmin was defined as the minimum observed plasma concentration. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| ng/mL | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 250 mg | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 400 mg/300 mg | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vepdegestrant: C1D15 | 125.3 ± 35.121 | 207.19 ± 8.3176 | 208.82 ± 54.16 | 380.95 ± 24.591 | 573.38 ± 44.962 | 444.36 ± 44.201 | 1420.8 ± 27.985 | 757.52 ± 35.202 | NA ± NA | 1020.9 ± 44.61 | NA ± NA |
| ARV-473: C1D15 | 48.45 ± 33.548 | 85.191 ± 1.7834 | 83.063 ± 64.476 | 142.73 ± 31.638 | 210.58 ± 39.478 | 174.72 ± 48.717 | 561.84 ± 43.197 | 290.01 ± 37.161 | NA ± NA | 365.46 ± 41.587 | NA ± NA |
CL/F was defined as the apparent oral plasma clearance of vepdegestrant. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| L/h | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 250 mg | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 400 mg/300 mg | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Part A: Apparent Oral Plasma Clearance (CL/F) of Vepdegestrant | 7.4 ± 25.6 | 8.19 ± 15.3 | 12.5 ± 40.1 | 8.75 ± 12.9 | 9.36 ± 31.8 | 12.7 ± 37.8 | 11.3 ± 28.8 | 13.9 ± 26.6 | NA ± NA | 14.5 ± 35.5 | NA ± NA |
Tmax was defined as the time of maximum observed plasma concentration. Based on predefined reporting convention in the SAP, summary statistics describing variability (median) was not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| hours | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 250 mg | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 400 mg/300 mg | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vepdegestrant: C1D1 | 4.02 (4.00 to 5.87) | 6.02 (4.00 to 6.10) | 5.75 (2.22 to 26.05) | 5.92 (4.03 to 7.82) | 5.98 (4.03 to 7.82) | 5.82 (4.00 to 7.75) | 6.86 (2.00 to 7.87) | 5.83 (3.98 to 7.78) | 4.13 (3.93 to 5.82) | 4.94 (0.95 to 7.95) | NA (5.75 to 5.75) |
| Vepdegestrant: C1D15 | 4.08 (3.92 to 6.00) | 4.15 (3.95 to 6.00) | 4.25 (1.87 to 7.98) | 5.92 (3.93 to 7.78) | 5.03 (2.08 to 5.97) | 4.05 (3.83 to 7.80) | 5.97 (1.97 to 7.92) | 5.77 (3.92 to 8.08) | NA (4.10 to 5.95) | 5.92 (3.83 to 7.78) | NA (5.95 to 5.95) |
| ARV-473: C1D1 | 24.00 (24.00 to 24.00) | 24.00 (24.00 to 24.00) | 24.00 (5.75 to 26.05) | 24.00 (7.67 to 24.00) | 24.00 (24.00 to 24.00) | 24.00 (24.00 to 24.92) | 7.78 (4.00 to 8.12) | 24.00 (24.00 to 24.00) | 7.80 (5.85 to 7.85) | 24.00 (6.05 to 24.00) | NA (24.00 to 24.00) |
| ARV-473: C1D15 | 6.03 (3.92 to 7.75) | 2.07 (1.02 to 5.88) | 5.97 (0.00 to 7.98) | 6.00 (3.92 to 7.78) | 5.88 (3.92 to 7.75) | 5.75 (1.03 to 7.85) | 4.05 (0.98 to 7.92) | 6.03 (1.98 to 8.75) | NA (5.88 to 5.95) | 6.00 (3.83 to 7.80) | NA (7.78 to 7.78) |
Rac was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| ratio | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 250 mg | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 400 mg/300 mg | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vepdegestrant | 2.36 ± 21.4 | 2.47 ± 18.8 | 2.19 ± 22.5 | 2.17 ± 18.6 | 2.01 ± 23.1 | 1.66 ± 49.1 | — | 2.13 ± 28.5 | — | 2.04 ± 39.6 | NA ± NA |
| ARV-473 | 6.61 ± 28.8 | 6.93 ± 27.5 | 6.14 ± 30.9 | 5.9 ± 30.4 | 5.7 ± 37.3 | 5.19 ± 49.7 | — | 5.97 ± 33.6 | — | 5.66 ± 48.5 | NA ± NA |
Rac was calculated as the ratio of Day 15/Day 1 based on Cmax. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| ratio | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 250 mg | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 400 mg/300 mg | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vepdegestrant | 2.01 ± 25.9 | 2.08 ± 24.9 | 1.99 ± 27.9 | 1.98 ± 16.4 | 1.78 ± 23.7 | 1.57 ± 56.6 | 3.3 ± 20.3 | 2.01 ± 23.1 | NA ± NA | 1.76 ± 35.6 | NA ± NA |
| ARV-473 | 5.23 ± 22.6 | 5.48 ± 40.6 | 5.15 ± 31.8 | 4.86 ± 28.9 | 4.49 ± 28.8 | 3.96 ± 53.8 | 13.7 ± 52.6 | 4.96 ± 37.9 | NA ± NA | 4.93 ± 50.4 | NA ± NA |
Effective half-life based on accumulation ratio of RAUC(0-tau). Accumulation ratio was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| hour | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 250 mg | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 400 mg/300 mg | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vepdegestrant | 30.8 ± 8.17 | 32.5 ± 7.57 | 28 ± 8.56 | 27.4 ± 7.5 | 24.8 ± 7.58 | 23 ± 13.4 | — | 27.5 ± 10.8 | — | 26.8 ± 14.6 | NA ± NA |
| ARV-473 | 104 ± 29.9 | 110 ± 30.6 | 98.3 ± 35.9 | 93.4 ± 32.2 | 91 ± 31.5 | 86 ± 42.9 | — | 95.6 ± 32.8 | — | 94.9 ± 47.8 | NA ± NA |
The epimer ARV-473 to parent ratio based on Cmax was reported. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| ratio | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 250 mg | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 400 mg/300 mg | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 0.101 ± 17.4 | 0.102 ± 10.9 | 0.0991 ± 24.8 | 0.0974 ± 33 | 0.105 ± 16.6 | 0.11 ± 20.4 | 0.0783 ± 27.3 | 0.103 ± 29.6 | 0.0662 ± 6.85 | 0.0937 ± 20 | NA ± NA |
| C1D15 | 0.263 ± 9.26 | 0.267 ± 7.87 | 0.274 ± 21.5 | 0.239 ± 19.8 | 0.257 ± 17.2 | 0.265 ± 23 | 0.344 ± 30.9 | 0.254 ± 26.9 | NA ± NA | 0.255 ± 26 | NA ± NA |
The epimer ARV-473 to parent ratio based on AUCtau was reported. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| ratio | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 250 mg | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 400 mg/300 mg | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 0.113 ± 3.42 | 0.109 ± 3.13 | 0.113 ± 12.9 | 0.107 ± 13.9 | 0.107 ± 10.9 | 0.105 ± 16.8 | — | 0.111 ± 16.1 | — | 0.107 ± 7.79 | NA ± NA |
| C1D15 | 0.316 ± 9.83 | 0.306 ± 7.59 | 0.325 ± 21 | 0.29 ± 17.3 | 0.302 ± 13.9 | 0.322 ± 14.7 | 0.367 ± 27.8 | 0.311 ± 15.2 | NA ± NA | 0.295 ± 18.5 | NA ± NA |
ORR was defined as the percentage of participants with best overall response (BOR) of CR and PR as per Response Evaluation Criteria in Solid Tumours (RECIST version \[v\] 1.1). BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR.
| percentage of participants | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|
| Part A: Overall Response Rate (ORR) by Investigator Per RECIST v1.1 | 0 (0.0 to 70.8) | 0 (0.0 to 84.2) | 25.0 (5.5 to 57.2) | 20.0 (0.5 to 71.6) | 0 (0.0 to 45.9) | 14.3 (0.4 to 57.9) | 18.2 (2.3 to 51.8) | 5.6 (0.1 to 27.3) | 0 (0.0 to 97.5) |
CBR: percentage of participants with summation of CR, PR or SD of 24 weeks duration or longer. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs.
| percentage of participants | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|
| Part A: Clinical Benefit Rate (CBR) | 33.3 (0.8 to 90.6) | 33.3 (0.8 to 90.6) | 42.9 (17.7 to 71.1) | 71.4 (29.0 to 96.3) | 14.3 (0.4 to 57.9) | 12.5 (0.3 to 52.7) | 40.0 (16.3 to 67.7) | 31.8 (13.9 to 54.9) | 50.0 (6.8 to 93.2) |
DCR: percentage of participants with CR, PR or SD. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. DCR was based on confirmed responses. Confirmed responses were at least 4 weeks after the criteria for response were first met.
| percentage of participants | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|
| Part A: Disease Control Rate (DCR) | 33.3 (0.8 to 90.6) | 33.3 (0.8 to 90.6) | 61.5 (31.6 to 86.1) | 85.7 (42.1 to 99.6) | 50.0 (11.8 to 88.2) | 25.0 (3.2 to 65.1) | 73.3 (44.9 to 92.2) | 47.4 (24.4 to 71.1) | 50.0 (6.8 to 93.2) |
PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Kaplan-Meier (KM) estimate was used for analysis.
| months | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|
| Part A: Progression-Free Survival (PFS) Per RECIST v1.1 | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.
| months | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) |
|---|---|---|---|---|---|---|---|---|---|
| Part A: Duration of Response | — | — | NA (NA to NA) | NA (NA to NA) | — | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | — |
ORR was defined as the percentage of participants with BOR of CR and PR as per RECIST version \[v\] 1.1. BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR.
| percentage of participants | Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) |
|---|---|---|
| Part B: Overall Response Rate (ORR) by Investigator Per RECIST v1.1 | 8.3 (1.0 to 27.0) | 14.3 (3.0 to 36.3) |
PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.
| months | Part B - Phase 2: Vepdegestrant 200 mg (Cohort Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Cohort Expansion) |
|---|---|---|
| Part B: Progression-Free Survival (PFS) Per RECIST v1.1 | 3.5 (1.8 to 7.8) | 5.4 (1.9 to 8.8) |
DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.
| months | Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) |
|---|---|---|
| Part B: Duration of Response | 10.4 (3.7 to NA) | 7.6 (5.7 to NA) |
OS was defined as the time from first dose of the study drug until the documented date of death from any cause. KM estimate was used for analysis.
| months | Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) |
|---|---|---|
| Part B: Overall Survival | NA (27.6 to NA) | NA (19.7 to NA) |
An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. SAE was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs.
| Participants | Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) |
|---|---|---|
| TEAEs | 32 | 34 |
| Serious TEAEs | 6 | 5 |
| Treatment-Related TEAEs | 30 | 27 |
Pre-dose Plasma concentrations of vepdegestrant and ARV-473 was reported. Based on predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| ng/mL | Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) |
|---|---|---|
| Vepdegestrant: C1D15 | 603.621 ± 422.4487 | 956.692 ± 403.4008 |
| Vepdegestrant: C1D28 | 637.783 ± 323.5315 | 1030.000 ± 590.7248 |
| Vepdegestrant: C2D28 | 527.143 ± 273.8017 | 839.313 ± 405.5787 |
| Vepdegestrant: C3D28 | 524.067 ± 236.7164 | 981.538 ± 457.8516 |
| Vepdegestrant: C4D28 | 525.727 ± 268.2164 | 918.532 ± 464.2570 |
| Vepdegestrant: C5D28 | 534.364 ± 245.3232 | 1148.100 ± 690.3299 |
| Vepdegestrant: C6D28 | 501.000 ± 302.0592 | 984.000 ± 417.0430 |
| Vepdegestrant: C7D28 | 444.444 ± 179.8285 | 957.333 ± 542.0904 |
| Vepdegestrant: C8D28 | 473.036 ± 282.8287 | 895.000 ± 383.0244 |
| Vepdegestrant: C9D28 | 387.500 ± 129.3922 | 1043.250 ± 288.6328 |
| Vepdegestrant: C10D28 | 436.500 ± 133.7223 | 1216.400 ± 638.9502 |
| Vepdegestrant: C11D28 | 404.000 ± 210.0286 | 1128.400 ± 427.0162 |
| Vepdegestrant: C12D28 | 410.000 ± NA | 1175.500 ± 445.2277 |
| Vepdegestrant: C13D28 | 504.000 ± 224.3056 | 974.000 ± 588.0034 |
| Vepdegestrant: C14D28 | 510.000 ± 222.0833 | 1134.000 ± 341.2096 |
| Vepdegestrant: C15D28 | 423.250 ± 244.6853 | 940.500 ± 547.7283 |
| Vepdegestrant: C16D28 | 451.750 ± 184.9709 | 1111.500 ± 536.1129 |
| Vepdegestrant: C17D28 | 488.500 ± 162.4346 | 1003.500 ± 601.5538 |
| Vepdegestrant: C18D28 | 477.667 ± 355.3594 | 1163.500 ± NA |
| Vepdegestrant: C19D28 | 303.500 ± NA | 1226.500 ± NA |
| Vepdegestrant: C20D28 | 468.000 ± NA | 382.000 ± NA |
| Vepdegestrant: C21D28 | 383.500 ± NA | 519.000 ± NA |
| Vepdegestrant: C22D28 | 666.000 ± NA | 470.000 ± NA |
| Vepdegestrant: C23D28 | 446.000 ± NA | 408.000 ± NA |
| Vepdegestrant: C24D28 | — | 536.000 ± NA |
| Vepdegestrant: C25D28 | — | 463.000 ± NA |
| Vepdegestrant: C26D28 | — | 549.000 ± NA |
| ARV-473: C1D15 | 245.43 ± 162.212 | 361.58 ± 166.885 |
| ARV-473: C1D28 | 272.78 ± 151.084 | 382.32 ± 242.746 |
| ARV-473: C2D28 | 219.26 ± 118.820 | 311.88 ± 144.295 |
| ARV-473: C3D28 | 206.77 ± 106.138 | 349.85 ± 149.663 |
| ARV-473: C4D28 | 187.34 ± 97.274 | 363.97 ± 184.902 |
| ARV-473: C5D28 | 199.14 ± 86.539 | 410.60 ± 200.839 |
| ARV-473: C6D28 | 175.32 ± 93.520 | 348.38 ± 142.711 |
| ARV-473: C7D28 | 180.06 ± 82.097 | 348.44 ± 172.105 |
| ARV-473: C8D28 | 184.99 ± 112.859 | 332.43 ± 153.503 |
| ARV-473: C9D28 | 143.48 ± 63.649 | 309.50 ± 109.061 |
| ARV-473: C10D28 | 175.25 ± 40.599 | 401.60 ± 171.221 |
| ARV-473: C11D28 | 147.57 ± 67.260 | 376.20 ± 131.665 |
| ARV-473: C12D28 | 158.50 ± NA | 416.75 ± 169.567 |
| ARV-473: C13D28 | 178.83 ± 76.819 | 341.00 ± 177.085 |
| ARV-473: C14D28 | 185.00 ± 75.439 | 437.00 ± 103.766 |
| ARV-473: C15D28 | 153.35 ± 64.547 | 337.75 ± 168.300 |
| ARV-473: C16D28 | 175.25 ± 61.711 | 392.50 ± 159.475 |
| ARV-473: C17D28 | 172.00 ± 78.456 | 364.00 ± 187.729 |
| ARV-473: C18D28 | 182.67 ± 143.309 | 393.50 ± NA |
| ARV-473: C19D28 | 125.50 ± NA | 406.00 ± NA |
| ARV-473: C20D28 | 189.00 ± NA | 165.00 ± NA |
| ARV-473: C21D28 | 181.50 ± NA | 222.00 ± NA |
| ARV-473: C22D28 | 263.00 ± NA | 203.00 ± NA |
| ARV-473: C23D28 | 181.00 ± NA | 169.00 ± NA |
| ARV-473: C24D28 | — | 214.00 ± NA |
| ARV-473: C25D28 | — | 221.00 ± NA |
| ARV-473: C26D28 | — | 219.00 ± NA |
AUCtau was calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant \& ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant \& ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for drug-drug interaction (DDI) evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| h*ng/mL | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| Vepdegestrant: C1D1 | NA ± NA | 7779.7 ± 42.146 | 14900 ± 27.65 | 16133 ± 29.712 | — |
| Vepdegestrant: C1D15 | NA ± NA | 18416 ± 46.658 | 21522 ± 8.0698 | 33367 ± 37.641 | — |
| Vepdegestrant: C1D21/C2D15 | — | — | — | — | 14216 ± 36.696 |
| ARV-473: C1D1 | NA ± NA | 931.33 ± 41.933 | 1402.6 ± 35.953 | 1833.1 ± 28.576 | — |
| ARV-473: C1D15 | NA ± NA | 6905.6 ± 57.501 | 6598.7 ± 10.195 | 11893 ± 44.365 | — |
| ARV-473: C1D21/C2D15 | — | — | — | — | 5186.3 ± 49.384 |
| Palbociclib: C1D1 | — | 907.67 ± 31.759 | NA ± NA | 819.86 ± 51.572 | — |
| Palbociclib: C1D8 | — | — | — | — | 1742.9 ± 33.966 |
| Palbociclib: C1D15 | — | 2902.9 ± 45.744 | 2571.1 ± 16.821 | 2992.1 ± 39.59 | — |
| Palbociclib: C1D21/C2D15 | — | — | — | — | 1804.9 ± 42.571 |
As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| h*ng/mL | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| Vepdegestrant: C1D1 | NA ± NA | 2351.2 ± 60.658 | 3864.9 ± 25.629 | 4754.7 ± 46.211 | — |
| Vepdegestrant: C1D15 | NA ± NA | 6493.1 ± 45.981 | 8274.6 ± 20.539 | 11378 ± 43.389 | — |
| Vepdegestrant: C1D21/C2D15 | — | — | — | — | 4940.9 ± 38.306 |
| ARV-473: C1D1 | NA ± NA | 165.52 ± 64.373 | 221.05 ± 28.37 | 316.86 ± 52.866 | — |
| ARV-473: C1D15 | NA ± NA | 2273.9 ± 53.045 | 2252 ± 14.983 | 3730.6 ± 47.654 | — |
| ARV-473: C1D21/C2D15 | — | — | — | — | 1693.5 ± 49.814 |
| Palbociclib: C1D1 | — | 253.98 ± 63.902 | NA ± NA | 219.28 ± 133.03 | — |
| Palbociclib: C1D8 | — | — | — | — | 620.4 ± 36.956 |
| Palbociclib: C1D15 | — | 987.34 ± 45.683 | 848.43 ± 21.093 | 929.8 ± 59.414 | — |
| Palbociclib: C1D21/C2D15 | — | — | — | — | 597.88 ± 42.112 |
As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| ng/mL | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| Vepdegestrant: C1D1 | NA ± NA | 506.3 ± 40.74 | 972.26 ± 22.31 | 980.86 ± 36.161 | — |
| Vepdegestrant: C1D15 | NA ± NA | 1046.4 ± 44.632 | 1347.8 ± 14.133 | 1795.5 ± 36.661 | — |
| Vepdegestrant: C1D21/C2D15 | — | — | — | — | 790.6 ± 35.141 |
| ARV-473: C1D1 | NA ± NA | 56.054 ± 35.146 | 87.066 ± 24.59 | 105.15 ± 32.657 | — |
| ARV-473: C1D15 | NA ± NA | 336.12 ± 55.493 | 334.13 ± 19.859 | 576.82 ± 48.933 | — |
| ARV-473: C1D21/C2D15 | — | — | — | — | 238.23 ± 47.27 |
| Palbociclib: C1D1 | — | 59.851 ± 32.502 | NA ± NA | 59.453 ± 56.309 | — |
| Palbociclib: C1D8 | — | — | — | — | 98.171 ± 39.202 |
| Palbociclib: C1D15 | — | 153.42 ± 45.26 | 127.46 ± 26.185 | 155.53 ± 39.057 | — |
| Palbociclib: C1D21/C2D15 | — | — | — | — | 95.999 ± 32.041 |
Cmin was defined as the minimum observed plasma concentration. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| ng/mL | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| Vepdegestrant: C1D15 | NA ± NA | 472.59 ± 81.959 | 637.02 ± 7.9382 | 1102.3 ± 42.598 | — |
| Vepdegestrant: C1D21/C2D15 | — | — | — | — | 420.7 ± 43.572 |
| ARV-473: C1D15 | NA ± NA | 199.89 ± 88.088 | 245.71 ± 8.7464 | 437.29 ± 42.344 | — |
| ARV-473: C1D21/C2D15 | — | — | — | — | 189.86 ± 51.056 |
| Palbociclib: C1D8 | — | — | — | — | 51.963 ± 39.374 |
| Palbociclib: C1D15 | — | 91.821 ± 48.474 | 88.771 ± 10.076 | 96.593 ± 46.645 | — |
| Palbociclib: C1D21/C2D15 | — | — | — | — | NA ± NA |
As planned for Part C, PK data of vepdegestrant and palbociclib for arms administered with 125 mg palbociclib was reported for C1D15. PK data of vepdegestrant data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| L/h | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| Vepdegestrant: C1D15 | NA ± NA | 10.9 ± 46.7 | 18.6 ± 8.07 | 15 ± 37.6 | — |
| Vepdegestrant: C1D21/C2D15 | — | — | — | — | 14.1 ± 36.7 |
| Palbociclib: C1D8 | — | — | — | — | 56.2 ± 35 |
| Palbociclib: C1D15 | — | 43.1 ± 45.7 | 48.6 ± 16.8 | 41.8 ± 39.6 | — |
| Palbociclib: C1D21/C2D15 | — | — | — | — | 55.4 ± 42.6 |
Tmax was defined as the time of maximum observed plasma concentration. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15, and palbociclib PK data for C1D8 and combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| hour | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| Vepdegestrant: C1D1 | NA (6.00 to 6.02) | 5.83 (1.92 to 23.92) | 7.78 (6.07 to 7.90) | 5.94 (1.85 to 7.80) | — |
| Vepdegestrant: C1D15 | NA (4.03 to 4.07) | 4.08 (2.00 to 8.08) | 5.92 (3.98 to 6.03) | 4.09 (2.03 to 7.75) | — |
| Vepdegestrant: C1D21/C2D15 | — | — | — | — | 5.96 (3.83 to 7.78) |
| ARV-473: C1D1 | NA (21.83 to 23.10) | 23.72 (5.83 to 28.83) | 23.98 (21.13 to 25.15) | 23.65 (7.78 to 27.48) | — |
| ARV-473: C1D15 | NA (4.03 to 8.03) | 7.77 (1.03 to 8.08) | 5.92 (3.98 to 6.03) | 4.14 (0.00 to 8.00) | — |
| ARV-473: C1D21/C2D15 | — | — | — | — | 5.91 (3.83 to 7.87) |
| Palbociclib: C1D1 | — | 6.10 (1.95 to 8.13) | NA (6.07 to 7.78) | 5.98 (1.83 to 27.48) | — |
| Palbociclib: C1D8 | — | — | — | — | 5.96 (1.00 to 7.92) |
| Palbociclib: C1D15 | — | 5.93 (0.00 to 8.08) | 5.92 (2.03 to 6.03) | 5.03 (0.00 to 7.92) | — |
| Palbociclib: C1D21/C2D15 | — | — | — | — | 6.00 (0.93 to 7.78) |
Rac was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. As prespecified, participants in the Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg Arm were not assessed. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| ratio | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| Vepdegestrant | NA ± NA | 2.29 ± 37.2 | 1.44 ± 27.2 | 2.05 ± 28.5 | — |
| ARV-473 | NA ± NA | 7.2 ± 40.2 | 4.7 ± 37.3 | 6.43 ± 37.2 | — |
| Palbociclib | — | 2.92 ± 16 | NA ± NA | 3.47 ± 41.7 | — |
Rac was calculated as the ratio of Day 15/Day 1 based on Cmax. Cmax was defined as the maximum observed plasma concentration obtained directly from the observed concentration versus time data. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. As prespecified, participants in the Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg Arm were not assessed. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| ratio | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| Vepdegestrant | NA ± NA | 1.96 ± 40.8 | 1.39 ± 14.5 | 1.79 ± 23.6 | — |
| ARV-473 | NA ± NA | 5.86 ± 32 | 3.84 ± 31.8 | 5.39 ± 39.5 | — |
| Palbociclib | — | 2.44 ± 24.4 | NA ± NA | 2.74 ± 48.2 | — |
Effective half-life based on accumulation ratio of RAUC(0-tau). Accumulation ratio was calculated as the ratio of Day 15/Day 1 based on AUCtau. AUCtau was defined as area under the concentration-time curve during a dosing interval calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. Based on the predefined reporting convention in the SAP, summary statistics describing variability (standard deviation/geometric coefficient of variation) were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| hours | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| Vepdegestrant | NA ± NA | 31.2 ± 15.3 | 14.5 ± 7.59 | 25.9 ± 9.91 | — |
| ARV-473 | NA ± NA | 120 ± 48.3 | 73.2 ± 31.6 | 104 ± 37 | — |
| Palbociclib | — | 40.2 ± 7.65 | NA ± NA | 53.7 ± 28.8 | — |
Epimer ARV-473 to parent ratio based on Cmax was reported. Cmax was defined as the maximum observed plasma concentration obtained from the observed concentration versus time data. As planned for Part C, PK data of vepdegestrant, ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1/C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21/C2D15. As per protocol, in 100 mg palbociclib administered arm, intensive PK sample collection not done on C1D21 was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| ratio | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| C1D1 | NA ± NA | 0.111 ± 33.3 | 0.0896 ± 3.39 | 0.107 ± 25.4 | — |
| C1D15 | NA ± NA | 0.321 ± 25.9 | 0.248 ± 13.5 | 0.321 ± 30.3 | — |
| C1D21/C2D15 | — | — | — | — | 0.301 ± 22.1 |
Epimer ARV-473 to parent ratio based on AUCtau was reported. AUCtau was calculated by linear up/log down trapezoidal summation. As planned for Part C, PK data of vepdegestrant and ARV-473 and palbociclib for arms administered with 125 mg palbociclib was reported for C1D1 and C1D15. PK data of vepdegestrant and ARV-473 data for arm administered with 100 mg palbociclib was reported for combined C1D21 and C2D15. As per protocol, in the arm administered with 100 mg palbociclib, if the intensive PK sample collection was not done on C1D21, it was postponed to C2D15. Only combined data on C1D21 and C2D15 represented all the data at the steady state of the combination of vepdegestrant 200 mg QD with palbociclib and were used for DDI evaluation. Based on predefined reporting convention in the SAP, summary statistics were not calculated or presented for analysis groups or timepoints if fewer than 3 participants had reportable parameter values.
| ratio | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| C1D1 | NA ± NA | 0.12 ± 17.3 | 0.0941 ± 9.21 | 0.114 ± 12.1 | — |
| C1D15 | NA ± NA | 0.375 ± 22.1 | 0.307 ± 2.12 | 0.356 ± 15.2 | — |
| C1D21/C2D15 | — | — | — | — | 0.365 ± 19.2 |
ORR was defined as the percentage of participants with BOR of CR and PR as per RECIST version \[v\] 1.1. BOR: best response was recorded from start of study treatment until disease progression or death due to any cause. CR was defined as disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR was defined as \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. Only participants with measurable disease at baseline were included in the analysis of ORR.
| percentage of participants | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| Part C: Overall Response Rate (ORR) by Investigator Per RECIST v1.1 | 0 (0.0 to 97.5) | 53.3 (26.6 to 78.7) | 0 (0.0 to 97.5) | 35.7 (12.8 to 64.9) | 14.3 (0.4 to 57.9) |
CBR: percentage of participants with summation of CR, PR or SD of 24 weeks duration or longer. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs.
| percentage of participants | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| Part C: Clinical Benefit Rate (CBR) | 100 (15.8 to 100.0) | 66.7 (43.0 to 85.4) | 100 (29.2 to 100) | 50.0 (27.2 to 72.8) | 29.4 (10.3 to 56.0) |
PFS: time from first dose of the study drug until date of documented radiological PD based on RECIST V1.1, or until death due to any cause, whichever occurred first. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.
| months | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| Part C: Progression-Free Survival (PFS) Per RECIST v1.1 | 11.1 (11.1 to NA) | 13.9 (8.0 to 19.3) | NA (23.1 to NA) | 5.6 (3.6 to 13.7) | 3.7 (2.1 to 8.5) |
OS was defined as the time from first dose of the study drug until the documented date of death from any cause. KM estimate was used for analysis.
| months | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| Part C: Overall Survival | NA (NA to NA) | 28.4 (26.9 to NA) | NA (28.3 to NA) | 23.4 (8.3 to NA) | NA (6.8 to NA) |
DOR was defined as the time interval from the date of first documented confirmed CR/PR to the date of PD or death, whichever occurred first per RECIST version v 1.1. CR: disappearance of all TLs and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the LD of TLs, taking as reference the baseline sum LD. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs. KM estimate was used for analysis.
| months | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|
| Part C: Duration of Response | — | 14.6 (4.5 to 15.9) | — | 13.8 (9.5 to NA) | 6.6 (NA to NA) |
Collected over AEs: From start of study treatment up to 30 days after EOT For Part A: Up to approx. 4 years and 6 months For Part B: Up to approx. 2 years and 11 months For Part C: Up to approx. 3 years and 9 months All-cause mortality: Part A: From enrollment up to 30 days after EOT For Part A: Up to approx. 4 years and 6 months For Part B Up to approx. 2 years and 11 months For Part C: Up to approx. 3 years and 9 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | 4/15 (26.7%) | 3/14 (21.4%) | 14/14 (100%) |
| Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | 5/7 (71.4%) | 0/7 (0%) | 7/7 (100%) |
| Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | 5/7 (71.4%) | 0/7 (0%) | 7/7 (100%) |
| Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | 4/8 (50%) | 1/8 (12.5%) | 8/8 (100%) |
| Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | 7/15 (46.7%) | 2/15 (13.3%) | 15/15 (100%) |
| Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | 15/22 (68.2%) | 2/22 (9.1%) | 21/22 (95.5%) |
| Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) | 2/4 (50%) | 1/4 (25%) | 3/4 (75%) |
| Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | 12/35 (34.3%) | 6/35 (17.1%) | 32/35 (91.4%) |
| Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) | 14/36 (38.9%) | 5/36 (13.9%) | 34/36 (94.4%) |
| Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | 6/21 (28.6%) | 8/21 (38.1%) | 21/21 (100%) |
| Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | 13/21 (61.9%) | 4/20 (20%) | 20/20 (100%) |
| Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) | 4/17 (23.5%) | 6/17 (35.3%) | 17/17 (100%) |
| Event | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) | Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corona virus infectionInfections and infestations | 0/3 | 0/3 | 0/14 | 0/7 | 0/7 | 0/8 | 0/15 | 0/22 | 0/4 | 0/35 | 0/36 | 1/2 | 0/21 | 0/3 | 0/20 | 0/17 |
| Procedural painInjury, poisoning and procedural complications | 1/3 | 0/3 | 0/14 | 0/7 | 0/7 | 0/8 | 0/15 | 0/22 | 0/4 | 0/35 | 0/36 | 0/2 | 0/21 | 0/3 | 0/20 | 0/17 |
| Spinal cord compressionNervous system disorders | 0/3 | 1/3 | 0/14 | 0/7 | 0/7 | 0/8 | 0/15 | 0/22 | 0/4 | 0/35 | 1/36 | 0/2 | 0/21 | 0/3 | 1/20 | 0/17 |
| Gastroenteritis viralInfections and infestations | 0/3 | 0/3 | 0/14 | 0/7 | 0/7 | 0/8 | 0/15 | 0/22 | 0/4 | 0/35 | 0/36 | 0/2 | 0/21 | 1/3 | 0/20 | 0/17 |
| Electrocardiogram QT prolongedInvestigations | 0/3 | 0/3 | 0/14 | 0/7 | 0/7 | 0/8 | 0/15 | 0/22 | 1/4 | 0/35 | 0/36 | 0/2 | 0/21 | 0/3 | 0/20 | 0/17 |
| ColitisGastrointestinal disorders | 0/3 | 0/3 | 0/14 | 0/7 | 0/7 | 1/8 | 0/15 | 0/22 | 0/4 | 0/35 | 0/36 | 0/2 | 0/21 | 0/3 | 0/20 | 0/17 |
| StomatitisGastrointestinal disorders | 0/3 | 0/3 | 0/14 | 0/7 | 0/7 | 1/8 | 0/15 | 0/22 | 0/4 | 0/35 | 0/36 | 0/2 | 0/21 | 0/3 | 0/20 | 0/17 |
| Neutrophil count decreasedInvestigations | 0/3 | 0/3 | 0/14 | 0/7 | 0/7 | 1/8 | 0/15 | 0/22 | 0/4 | 0/35 | 0/36 | 0/2 | 0/21 | 0/3 | 0/20 | 0/17 |
| AscitesGastrointestinal disorders | 0/3 | 0/3 | 0/14 | 0/7 | 0/7 | 0/8 | 0/15 | 0/22 | 0/4 | 0/35 | 0/36 | 0/2 | 0/21 | 0/3 | 0/20 | 2/17 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/14 | 0/7 | 0/7 | 0/8 | 0/15 | 0/22 | 0/4 | 0/35 | 0/36 | 0/2 | 2/21 | 0/3 | 0/20 | 1/17 |
| Event | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) | Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 0/3 | 0/14 | 1/7 | 1/7 | 0/8 | 0/15 | 0/22 | 0/4 | 0/35 | 0/36 | 2/2 | 7/21 | 0/3 | 8/20 | 2/17 |
| FatigueGeneral disorders | 0/3 | 1/3 | 6/14 | 1/7 | 2/7 | 4/8 | 6/15 | 13/22 | 2/4 | 18/35 | 16/36 | 2/2 | 14/21 | 1/3 | 13/20 | 8/17 |
| Corona virus infectionInfections and infestations | 0/3 | 0/3 | 1/14 | 0/7 | 0/7 | 0/8 | 0/15 | 1/22 | 0/4 | 2/35 | 2/36 | 2/2 | 2/21 | 0/3 | 2/20 | 1/17 |
| Neutrophil count decreasedInvestigations | 0/3 | 0/3 | 1/14 | 0/7 | 0/7 | 0/8 | 1/15 | 2/22 | 1/4 | 5/35 | 2/36 | 1/2 | 14/21 | 3/3 | 14/20 | 11/17 |
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/3 | 1/14 | 0/7 | 0/7 | 2/8 | 2/15 | 0/22 | 1/4 | 4/35 | 6/36 | 0/2 | 9/21 | 2/3 | 8/20 | 3/17 |
| ConstipationGastrointestinal disorders | 0/3 | 2/3 | 5/14 | 2/7 | 1/7 | 2/8 | 5/15 | 11/22 | 1/4 | 5/35 | 9/36 | 0/2 | 7/21 | 0/3 | 6/20 | 4/17 |
| DiarrhoeaGastrointestinal disorders | 0/3 | 0/3 | 6/14 | 0/7 | 0/7 | 1/8 | 4/15 | 3/22 | 1/4 | 3/35 | 3/36 | 1/2 | 5/21 | 2/3 | 4/20 | 3/17 |
| NauseaGastrointestinal disorders | 0/3 | 2/3 | 3/14 | 2/7 | 2/7 | 3/8 | 5/15 | 9/22 | 2/4 | 9/35 | 12/36 | 1/2 | 4/21 | 1/3 | 9/20 | 5/17 |
| Platelet count decreasedInvestigations | 0/3 | 0/3 | 0/14 | 0/7 | 1/7 | 0/8 | 0/15 | 1/22 | 0/4 | 0/35 | 0/36 | 0/2 | 11/21 | 2/3 | 10/20 | 4/17 |
| White blood cell count decreasedInvestigations | 0/3 | 0/3 | 2/14 | 0/7 | 0/7 | 0/8 | 1/15 | 1/22 | 1/4 | 3/35 | 2/36 | 0/2 | 6/21 | 2/3 | 6/20 | 2/17 |
The All-Treated Analysis Set consisted of all enrolled participants who had received any amount of vepdegestrant dose (partial or complete) for monotherapy cohorts or any study drug for combination therapy cohorts.
| Age, Continuous(years) | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) | Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 69.0 ± 2.65 | 67.3 ± 2.89 | 62.1 ± 11.80 | 63.1 ± 11.04 | 62.7 ± 9.96 | 61.5 ± 11.66 | 64.3 ± 8.19 | 58.9 ± 11.46 | 63.5 ± 9.04 | 60.1 ± 10.46 | 59.6 ± 9.56 | 59.5 ± 4.95 | 63.8 ± 11.50 | 52.3 ± 10.97 | 58.3 ± 10.15 | 62.4 ± 12.12 | 61.07 ± 10.44 |
| Sex: Female, Male(Participants) | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) | Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 3 | 13 | 7 | 7 | 8 | 15 | 22 | 4 | 34 | 35 | 2 | 20 | 3 | 20 | 15 | 211 |
| Male | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 2 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) | Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 2 | 0 | 12 |
| Not Hispanic or Latino | 3 | 3 | 12 | 7 | 6 | 8 | 12 | 22 | 4 | 33 | 30 | 2 | 21 | 3 | 17 | 17 | 200 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 5 |
| Race (NIH/OMB)(Participants) | Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) | Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) | Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) | Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) | Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) | Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion) | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 2 | 0 | 2 | 0 | 0 | 1 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 6 |
| White | 3 | 3 | 11 | 7 | 5 | 7 | 14 | 19 | 4 | 30 | 31 | 2 | 19 | 3 | 17 | 16 | 191 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 3 | 2 | 0 | 0 | 0 | 2 | 0 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2019 to primary completion in Sep 2024, 59 months.
Results were first posted in Sep 2026, 2 years after primary completion. A results delay was requested in Sep 2025.
Of 161 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's 59 months is close to that.
Counting every sponsor, half of 328 studies reached it within 61 months; a quarter within 45 and three quarters within 88.
Start moved once since we started tracking on Sep 25, 2026: Aug 2019 → Sep 2019, on Sep 29, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) · Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) · Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) · Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) · Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation) · Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation) · Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion) · Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation) · Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation) · Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion) · Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vepdegestrant
Arvinas Estrogen Receptor, Inc.